Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Immunomodulators
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Disorder Therapeutics Market Growth by Application: 2018 VS 2024 VS 2034
1.3.2 Multiple Sclerosis
1.3.3 Parkinson'S Disease
1.3.4 Alzheimer'S Disease
1.3.5 Spinal Muscular Atrophy
1.3.6 Huntington Disease
1.3.7 Other Neurodegenerative Disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disorder Therapeutics Market Perspective (2018-2034)
2.2 Neurodegenerative Disorder Therapeutics Growth Trends by Region
2.2.1 Global Neurodegenerative Disorder Therapeutics Market Size by Region: 2018 VS 2024 VS 2034
2.2.2 Neurodegenerative Disorder Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2024-2034)
2.3 Neurodegenerative Disorder Therapeutics Market Dynamics
2.3.1 Neurodegenerative Disorder Therapeutics Industry Trends
2.3.2 Neurodegenerative Disorder Therapeutics Market Drivers
2.3.3 Neurodegenerative Disorder Therapeutics Market Challenges
2.3.4 Neurodegenerative Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Disorder Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Neurodegenerative Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Disorder Therapeutics Revenue
3.4 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disorder Therapeutics Revenue in 2024
3.5 Neurodegenerative Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Neurodegenerative Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Disorder Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2024-2034)
5 Neurodegenerative Disorder Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Disorder Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Neurodegenerative Disorder Therapeutics Market Size (2018-2034)
6.2 North America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2024 VS 2034
6.3 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
6.4 North America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Disorder Therapeutics Market Size (2018-2034)
7.2 Europe Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2024 VS 2034
7.3 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
7.4 Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size (2018-2034)
8.2 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Growth Rate by Region: 2018 VS 2024 VS 2034
8.3 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Disorder Therapeutics Market Size (2018-2034)
9.2 Latin America Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2024 VS 2034
9.3 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size (2018-2034)
10.2 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Growth Rate by Country: 2018 VS 2024 VS 2034
10.3 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen, Inc.
11.1.1 Biogen, Inc. Company Detail
11.1.2 Biogen, Inc. Business Overview
11.1.3 Biogen, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.1.4 Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.1.5 Biogen, Inc. Recent Development
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Detail
11.2.2 Pfizer, Inc. Business Overview
11.2.3 Pfizer, Inc. Neurodegenerative Disorder Therapeutics Introduction
11.2.4 Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.2.5 Pfizer, Inc. Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Neurodegenerative Disorder Therapeutics Introduction
11.3.4 Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 Sanofi S.A.
11.4.1 Sanofi S.A. Company Detail
11.4.2 Sanofi S.A. Business Overview
11.4.3 Sanofi S.A. Neurodegenerative Disorder Therapeutics Introduction
11.4.4 Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.4.5 Sanofi S.A. Recent Development
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.6 UCB S.A.
11.6.1 UCB S.A. Company Detail
11.6.2 UCB S.A. Business Overview
11.6.3 UCB S.A. Neurodegenerative Disorder Therapeutics Introduction
11.6.4 UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.6.5 UCB S.A. Recent Development
11.7 F. Hoffmann- La Roche Ltd.
11.7.1 F. Hoffmann- La Roche Ltd. Company Detail
11.7.2 F. Hoffmann- La Roche Ltd. Business Overview
11.7.3 F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Introduction
11.7.4 F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.7.5 F. Hoffmann- La Roche Ltd. Recent Development
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Detail
11.8.2 H. Lundbeck Business Overview
11.8.3 H. Lundbeck Neurodegenerative Disorder Therapeutics Introduction
11.8.4 H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.8.5 H. Lundbeck Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Detail
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Neurodegenerative Disorder Therapeutics Introduction
11.9.4 Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.9.5 Merck KGaA Recent Development
11.10 GlaxoSmithKline PLC
11.10.1 GlaxoSmithKline PLC Company Detail
11.10.2 GlaxoSmithKline PLC Business Overview
11.10.3 GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Introduction
11.10.4 GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.10.5 GlaxoSmithKline PLC Recent Development
11.11 AbbVie Inc.
11.11.1 AbbVie Inc. Company Detail
11.11.2 AbbVie Inc. Business Overview
11.11.3 AbbVie Inc. Neurodegenerative Disorder Therapeutics Introduction
11.11.4 AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.11.5 AbbVie Inc. Recent Development
11.12 Bristol Myers Squibb Company
11.12.1 Bristol Myers Squibb Company Company Detail
11.12.2 Bristol Myers Squibb Company Business Overview
11.12.3 Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Introduction
11.12.4 Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.12.5 Bristol Myers Squibb Company Recent Development
11.13 Boehringer Ingeiheim International GmbH
11.13.1 Boehringer Ingeiheim International GmbH Company Detail
11.13.2 Boehringer Ingeiheim International GmbH Business Overview
11.13.3 Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Introduction
11.13.4 Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.13.5 Boehringer Ingeiheim International GmbH Recent Development
11.14 Bayer AG
11.14.1 Bayer AG Company Detail
11.14.2 Bayer AG Business Overview
11.14.3 Bayer AG Neurodegenerative Disorder Therapeutics Introduction
11.14.4 Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.14.5 Bayer AG Recent Development
11.15 Eisai Co., Ltd
11.15.1 Eisai Co., Ltd Company Detail
11.15.2 Eisai Co., Ltd Business Overview
11.15.3 Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Introduction
11.15.4 Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023)
11.15.5 Eisai Co., Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2024 VS 2034
Table 2. Key Players of Immunomodulators
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Disorder Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2024 VS 2034
Table 8. Global Neurodegenerative Disorder Therapeutics Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 9. Global Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2018-2023)
Table 11. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 12. Global Neurodegenerative Disorder Therapeutics Market Share by Region (2024-2034)
Table 13. Neurodegenerative Disorder Therapeutics Market Trends
Table 14. Neurodegenerative Disorder Therapeutics Market Drivers
Table 15. Neurodegenerative Disorder Therapeutics Market Challenges
Table 16. Neurodegenerative Disorder Therapeutics Market Restraints
Table 17. Global Neurodegenerative Disorder Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Neurodegenerative Disorder Therapeutics Market Share by Players (2018-2023)
Table 19. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2024)
Table 20. Ranking of Global Top Neurodegenerative Disorder Therapeutics Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Disorder Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Disorder Therapeutics Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Disorder Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Disorder Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2018-2023)
Table 28. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 29. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Type (2024-2034)
Table 30. Global Neurodegenerative Disorder Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2018-2023)
Table 32. Global Neurodegenerative Disorder Therapeutics Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 33. Global Neurodegenerative Disorder Therapeutics Revenue Market Share by Application (2024-2034)
Table 34. North America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 35. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 37. Europe Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 40. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2024 VS 2034
Table 41. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size by Region (2024-2034) & (US$ Million)
Table 43. Latin America Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 49. Biogen, Inc. Company Detail
Table 50. Biogen, Inc. Business Overview
Table 51. Biogen, Inc. Neurodegenerative Disorder Therapeutics Product
Table 52. Biogen, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 53. Biogen, Inc. Recent Development
Table 54. Pfizer, Inc. Company Detail
Table 55. Pfizer, Inc. Business Overview
Table 56. Pfizer, Inc. Neurodegenerative Disorder Therapeutics Product
Table 57. Pfizer, Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 58. Pfizer, Inc. Recent Development
Table 59. Novartis AG Company Detail
Table 60. Novartis AG Business Overview
Table 61. Novartis AG Neurodegenerative Disorder Therapeutics Product
Table 62. Novartis AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 63. Novartis AG Recent Development
Table 64. Sanofi S.A. Company Detail
Table 65. Sanofi S.A. Business Overview
Table 66. Sanofi S.A. Neurodegenerative Disorder Therapeutics Product
Table 67. Sanofi S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 68. Sanofi S.A. Recent Development
Table 69. Teva Pharmaceutical Industries Ltd. Company Detail
Table 70. Teva Pharmaceutical Industries Ltd. Business Overview
Table 71. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disorder Therapeutics Product
Table 72. Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 73. Teva Pharmaceutical Industries Ltd. Recent Development
Table 74. UCB S.A. Company Detail
Table 75. UCB S.A. Business Overview
Table 76. UCB S.A. Neurodegenerative Disorder Therapeutics Product
Table 77. UCB S.A. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 78. UCB S.A. Recent Development
Table 79. F. Hoffmann- La Roche Ltd. Company Detail
Table 80. F. Hoffmann- La Roche Ltd. Business Overview
Table 81. F. Hoffmann- La Roche Ltd. Neurodegenerative Disorder Therapeutics Product
Table 82. F. Hoffmann- La Roche Ltd. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 83. F. Hoffmann- La Roche Ltd. Recent Development
Table 84. H. Lundbeck Company Detail
Table 85. H. Lundbeck Business Overview
Table 86. H. Lundbeck Neurodegenerative Disorder Therapeutics Product
Table 87. H. Lundbeck Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 88. H. Lundbeck Recent Development
Table 89. Merck KGaA Company Detail
Table 90. Merck KGaA Business Overview
Table 91. Merck KGaA Neurodegenerative Disorder Therapeutics Product
Table 92. Merck KGaA Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 93. Merck KGaA Recent Development
Table 94. GlaxoSmithKline PLC Company Detail
Table 95. GlaxoSmithKline PLC Business Overview
Table 96. GlaxoSmithKline PLC Neurodegenerative Disorder Therapeutics Product
Table 97. GlaxoSmithKline PLC Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 98. GlaxoSmithKline PLC Recent Development
Table 99. AbbVie Inc. Company Detail
Table 100. AbbVie Inc. Business Overview
Table 101. AbbVie Inc. Neurodegenerative Disorder Therapeutics Product
Table 102. AbbVie Inc. Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 103. AbbVie Inc. Recent Development
Table 104. Bristol Myers Squibb Company Company Detail
Table 105. Bristol Myers Squibb Company Business Overview
Table 106. Bristol Myers Squibb Company Neurodegenerative Disorder Therapeutics Product
Table 107. Bristol Myers Squibb Company Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 108. Bristol Myers Squibb Company Recent Development
Table 109. Boehringer Ingeiheim International GmbH Company Detail
Table 110. Boehringer Ingeiheim International GmbH Business Overview
Table 111. Boehringer Ingeiheim International GmbH Neurodegenerative Disorder Therapeutics Product
Table 112. Boehringer Ingeiheim International GmbH Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 113. Boehringer Ingeiheim International GmbH Recent Development
Table 114. Bayer AG Company Detail
Table 115. Bayer AG Business Overview
Table 116. Bayer AG Neurodegenerative Disorder Therapeutics Product
Table 117. Bayer AG Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 118. Bayer AG Recent Development
Table 119. Eisai Co., Ltd Company Detail
Table 120. Eisai Co., Ltd Business Overview
Table 121. Eisai Co., Ltd Neurodegenerative Disorder Therapeutics Product
Table 122. Eisai Co., Ltd Revenue in Neurodegenerative Disorder Therapeutics Business (2018-2023) & (US$ Million)
Table 123. Eisai Co., Ltd Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Disorder Therapeutics Market Size Comparison by Type (2023-2034) & (US$ Million)
Figure 2. Global Neurodegenerative Disorder Therapeutics Market Share by Type: 2024 VS 2034
Figure 3. Immunomodulators Features
Figure 4. Interferons Features
Figure 5. Decarboxylase Inhibitors Features
Figure 6. Dopamine Agonists Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Disorder Therapeutics Market Size Comparison by Application (2023-2034) & (US$ Million)
Figure 9. Global Neurodegenerative Disorder Therapeutics Market Share by Application: 2024 VS 2034
Figure 10. Multiple Sclerosis Case Studies
Figure 11. Parkinson'S Disease Case Studies
Figure 12. Alzheimer'S Disease Case Studies
Figure 13. Spinal Muscular Atrophy Case Studies
Figure 14. Huntington Disease Case Studies
Figure 15. Other Neurodegenerative Disorders Case Studies
Figure 16. Neurodegenerative Disorder Therapeutics Report Years Considered
Figure 17. Global Neurodegenerative Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 18. Global Neurodegenerative Disorder Therapeutics Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 19. Global Neurodegenerative Disorder Therapeutics Market Share by Region: 2024 VS 2034
Figure 20. Global Neurodegenerative Disorder Therapeutics Market Share by Players in 2024
Figure 21. Global Top Neurodegenerative Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disorder Therapeutics as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Neurodegenerative Disorder Therapeutics Revenue in 2024
Figure 23. North America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. North America Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2034)
Figure 25. United States Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 26. Canada Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. Europe Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 28. Europe Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2034)
Figure 29. Germany Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. France Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. U.K. Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Italy Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. Russia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Nordic Countries Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Share by Region (2018-2034)
Figure 37. China Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 38. Japan Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 39. South Korea Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 40. Southeast Asia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 41. India Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 42. Australia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. Latin America Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. Latin America Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2034)
Figure 45. Mexico Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 46. Brazil Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 48. Middle East & Africa Neurodegenerative Disorder Therapeutics Market Share by Country (2018-2034)
Figure 49. Turkey Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 50. Saudi Arabia Neurodegenerative Disorder Therapeutics Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 51. Biogen, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 52. Pfizer, Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 53. Novartis AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 54. Sanofi S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 55. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 56. UCB S.A. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 57. F. Hoffmann- La Roche Ltd. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 58. H. Lundbeck Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 59. Merck KGaA Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 60. GlaxoSmithKline PLC Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 61. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 62. Bristol Myers Squibb Company Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 63. Boehringer Ingeiheim International GmbH Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 64. Bayer AG Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 65. Eisai Co., Ltd Revenue Growth Rate in Neurodegenerative Disorder Therapeutics Business (2018-2023)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed